Next-Generation Lipid Formulations for RNA-Based Immunotherapy

This inventive concept envisions a next-generation lipid formulation technology for RNA-based immunotherapy, offering improved safety, efficacy, and personalization through reduced immunogenicity and targeted immune cell delivery.

The original patent on lipid formulations with RNA encoding immunogens provided a significant breakthrough in non-viral delivery of RNA for immunization. However, there remains a need for further improvements in reducing adverse immune responses and enhancing targeted delivery to specific immune cells. This inventive concept addresses these limitations by introducing novel modifications to the RNA and lipid particles, enabling a safer and more effective RNA-based immunotherapy.

The new inventive concept comprises a lipid nanoparticle-based vector designed to target specific immune cells, wherein the RNA is modified to have a reduced immunogenicity profile. This is achieved through the incorporation of a cap structure with a 5'-methylated ribose, reducing the immunogenicity of the RNA. The lipid particles are engineered to comprise from 1 mole % to 6 mole % of a PEG-conjugated lipid, enhancing targeted delivery to immune cells. The system can be adapted for personalized RNA-based immunotherapy, allowing for individual patient responses to be addressed.

The new claims introduce the concept of modifying the RNA to have a reduced immunogenicity profile, which is a significant departure from the original patent. The targeted delivery of RNA to specific immune cells using lipid nanoparticles is also a novel aspect of this inventive concept. These advancements provide a non-obvious solution to the limitations of the original patent, offering improved safety and efficacy in RNA-based immunotherapy.

Alternative embodiments of this inventive concept could include the use of different types of lipid nanoparticles, varying the percentage of PEG-conjugated lipid, or incorporating additional modifications to the RNA. The system could also be adapted for use in different disease indications, such as cancer or infectious diseases.

The next-generation lipid formulation technology for RNA-based immunotherapy has significant commercial potential in the pharmaceutical industry, particularly in the fields of infectious diseases, cancer, and personalized medicine. The market for RNA-based immunotherapy is expected to grow substantially in the coming years, and this inventive concept is well-positioned to capture a significant share of this market.